Vaccinex, Inc. (NASDAQ:VCNX) Director Jacob B. Frieberg bought 90,090 shares of the company’s stock in a transaction on Thursday, January 27th. The stock was purchased at an average cost of $1.11 per share, for a total transaction of $99,999.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
NASDAQ:VCNX traded up $0.38 on Monday, hitting $1.51. The stock had a trading volume of 4,000,407 shares, compared to its average volume of 2,842,601. The company has a debt-to-equity ratio of 0.10, a quick ratio of 6.86 and a current ratio of 6.86. The business has a 50-day moving average price of $1.29. Vaccinex, Inc. has a 52-week low of $0.90 and a 52-week high of $9.56.
Vaccinex (NASDAQ:VCNX) last announced its earnings results on Monday, November 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.12. The firm had revenue of $0.05 million during the quarter.
Several hedge funds and other institutional investors have recently bought and sold shares of VCNX. Natixis bought a new position in shares of Vaccinex in the third quarter worth about $69,000. Virtu Financial LLC raised its stake in shares of Vaccinex by 103.9% in the second quarter. Virtu Financial LLC now owns 38,026 shares of the company’s stock worth $106,000 after buying an additional 19,374 shares during the period. State Street Corp bought a new position in shares of Vaccinex in the second quarter worth about $188,000. Geode Capital Management LLC raised its stake in shares of Vaccinex by 23.3% in the third quarter. Geode Capital Management LLC now owns 128,332 shares of the company’s stock worth $277,000 after buying an additional 24,218 shares during the period. Finally, Telemetry Investments L.L.C. raised its stake in shares of Vaccinex by 10.4% in the third quarter. Telemetry Investments L.L.C. now owns 132,500 shares of the company’s stock worth $286,000 after buying an additional 12,500 shares during the period. 5.08% of the stock is currently owned by hedge funds and other institutional investors.
Vaccinex, Inc operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington’s disease.
Featured Article: Penny Stocks
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Vaccinex, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Vaccinex wasn’t on the list.
While Vaccinex currently has a “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.